Wang Sheng, Yu Guocan, Wang Zhantong, Jacobson Orit, Tian Rui, Lin Li-Sen, Zhang Fuwu, Wang Jing, Chen Xiaoyuan
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.
Adv Mater. 2018 Aug 31:e1803926. doi: 10.1002/adma.201803926.
Nanomedicines have been demonstrated to have passive or active tumor targeting behaviors, which are promising for cancer chemotherapy. However, most nanomedicines still suffer from a suboptimal targeting effect and drug leakage, resulting in unsatisfactory treatment outcome. Herein, a hierarchical responsive nanomedicine (HRNM) is developed for programmed delivery of chemotherapeutics. The HRNMs are prepared via the self-assembly of cyclic Arg-Gly-Asp (RGD) peptide conjugated triblock copolymer, poly(2-(hexamethyleneimino)ethyl methacrylate)-poly(oligo-(ethylene glycol) monomethyl ether methacrylate)-poly[reduction-responsive camptothecin] (PC7A-POEG-PssCPT). In blood circulation, the RGD peptides are shielded by the POEG coating; therefore, the nanosized HRNMs can achieve effective tumor accumulation through passive targeting. Once the HRNMs reach a tumor site, due to the hydrophobic-tohydrophilic conversion of PC7A chains induced by the acidic tumor microenvironment, the RGD peptides will be exposed for enhanced tumor retention and cellular internalization. Moreover, in response to the glutathione inside cells, active CPT drugs will be released rapidly for chemotherapy. The in vitro and in vivo results confirm effective tumor targeting, potent antitumor effect, and reduced systemic toxicity of the HRNMs. This HRNM is promising for enhanced chemotherapeutic delivery.
纳米药物已被证明具有被动或主动的肿瘤靶向行为,这对于癌症化疗很有前景。然而,大多数纳米药物仍然存在靶向效果欠佳和药物泄漏的问题,导致治疗效果不尽人意。在此,开发了一种用于化疗药物程序化递送的分级响应纳米药物(HRNM)。HRNMs通过环化精氨酸-甘氨酸-天冬氨酸(RGD)肽共轭三嵌段共聚物聚(2-(六亚甲基亚氨基)乙基甲基丙烯酸酯)-聚(聚乙二醇单甲醚甲基丙烯酸酯)-聚[还原响应喜树碱](PC7A-POEG-PssCPT)的自组装制备。在血液循环中,RGD肽被POEG涂层屏蔽;因此,纳米尺寸的HRNMs可以通过被动靶向实现有效的肿瘤蓄积。一旦HRNMs到达肿瘤部位,由于酸性肿瘤微环境诱导PC7A链从疏水向亲水转变,RGD肽将被暴露,以增强肿瘤滞留和细胞内化。此外,响应细胞内的谷胱甘肽,活性喜树碱药物将迅速释放用于化疗。体外和体内结果证实了HRNMs有效的肿瘤靶向性、强大的抗肿瘤作用和降低的全身毒性。这种HRNM在增强化疗药物递送方面很有前景。